Medical Uses
PRAXBIND (idarucizumab), from Boehringer Ingelheim, is indicated for the reversal of the anticoagulant effects of dabigatran (Pradaxa) in emergency surgery/urgent procedures or in life-threatening/uncontrolled bleeding.
Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with high affinity, neutralizing its anticoagulant effect almost immediately, providing a targeted reversal agent distinct from general clotting-factor approaches.
